#USA #Cranford #CTCL #LYMPHIR #Citius Oncology

Citius Oncology Reports Growth in LYMPHIR Sales Amid Commercial Expansion

Citius Oncology, Inc. (Nasdaq: CTOR) recently announced promising updates regarding its innovative cancer treatment, LYMPHIR® (denileukin diftitox-cxdl). As an oncology-focused biopharmaceutical company and a major subsidiary of Citius Pharmaceuticals, the firm has been experiencing robust commercial momentum, particularly as more institutions are ordering its product.

Key Highlights

During the last quarter, Citius Oncology reported that new institutional accounts ordering LYMPHIR surged by 78% compared to the previous quarter. This leap indicates a growing recognition and acceptance of the treatment among healthcare providers. LYMPHIR is primarily designed to treat patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

Moreover, Citius has successfully expanded LYMPHIR's market access thanks to near-universal payer coverage, which facilitates widespread prescribing capabilities in the U.S. health system. With the CTCL market being valued at over $400 million and growing, Citius Oncology is strategically well-positioned to increase its footprint in this sector.

Expansion and Engagement

Leadership at Citius, represented by Chairman and CEO Leonard Mazur, emphasized that the company’s recent commercial progress is linked to two key factors: the rising number of institutions ordering LYMPHIR and the progressive formulary approvals needed to ensure broader availability. As of now, LYMPHIR is being dispensed in 42 institutions nationwide, including top academic oncology centers and community infusion centers.

Mazur shared, “The number of new institutions ordering LYMPHIR rose significantly, and we are seeing substantial demand reflected in our wholesale orders.” This uptick is crucial since the order fulfillment from wholesalers results in revenue recognition for Citius. With an ambition to add over 20 more institutions by the end of the current quarter, the company aims to have 100 priority institutions approved for formularies by year-end.

Dialogue with Healthcare Professionals

Citius Oncology takes pride in its proactive engagement with leading CTCL experts, facilitating a scientific exchange that builds stronger relationships and trust within the medical community. The company's medical affairs team has been tasked with educating these specialists about LYMPHIR’s clinical efficacy, thereby supporting its evaluation and consideration in clinical practices.

This initiative was underscored at the Sixth World Congress of Cutaneous Lymphomas held recently in Montreal, where Citius representatives connected with a plethora of U.S. and international key opinion leaders to discuss the therapy's profile and benefits.

Important Safety Information

LYMPHIR, an IL-2 receptor-targeted therapy, is utilized in treating adult patients suffering from Stage I-III CTCL following previous systemic treatment attempts. It works as a recombinant fusion protein, effectively binding to IL-2 receptors on the surface of tumor cells and inducing cell death via toxin mechanisms. While the drug has demonstrated promising success, it is pertinent to note its potential side effects, which include capillary leak syndrome, visual impairment, and infusion-related reactions. Routine monitoring and patient assessment remain essential to ensure safe usage.

Despite these challenges, Citius Oncology's management remains confident about LYMPHIR’s commercial potential, leveraging extensive intellectual property protections and exploring strategic partnerships to reinforce its competitive stance in the oncology landscape.

Citius Oncology continues to be optimistic about LYMPHIR’s growing acceptance in the medical community as they facilitate ongoing education and patient care initiatives, ensuring that eligible patients can benefit from this targeted therapy. As they approach the latter half of the year, Citius aims for sustained growth and improved patient outcomes with LYMPHIR.

For more information about Citius Oncology and its offerings, please visit Citius Oncology's Website.